Dragos Vinereanu1, Renato D Lopes2, M Cecilia Bahit3, Denis Xavier4, Jie Jiang5, Hussein R Al-Khalidi6, Wensheng He6, Ying Xian7, Andrea O Ciobanu1, Deepak Y Kamath4, Kathleen A Fox6, Meena P Rao6, Sean D Pokorney6, Otavio Berwanger8, Carlos Tajer9, Pedro G M de Barros E Silva8, Mayme L Roettig6, Yong Huo5, Christopher B Granger10. 1. University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Romania. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; Federal University of São Paulo, São Paulo, Brazil; Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil. 3. INECO Neurociencias, Rosario, Argentina; Argentine Clinical Research Group (ACRG), Rosario, Argentina. 4. St John's Medical College and Research Institute, Bangalore, India. 5. Peking University First Hospital, Beijing, China. 6. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. 7. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; Department of Neurology, Duke University Medical Center, Durham, NC, USA. 8. Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil; Research Institute HCor, Heart Hospital (Hospital do Coração), Sao Paulo-SP, Brazil. 9. Hospital El Cruce, Buenos Aires, Argentina. 10. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. Electronic address: christopher.granger@duke.edu.
Abstract
BACKGROUND:Oral anticoagulation is underused in patients with atrial fibrillation. We assessed the impact of a multifaceted educational intervention, versus usual care, on oral anticoagulant use in patients with atrial fibrillation. METHODS: This study was a two-arm, prospective, international, cluster-randomised, controlled trial. Patients were included who had atrial fibrillation and an indication for oral anticoagulation. Clusters were randomised (1:1) to receive a quality improvement educational intervention (intervention group) or usual care (control group). Randomisation was carried out centrally, using the eClinicalOS electronic data capture system. The intervention involved education of providers and patients, with regular monitoring and feedback. The primary outcome was the change in the proportion of patients treated with oral anticoagulants from baseline assessment to evaluation at 1 year. The trial is registered at ClinicalTrials.gov, number NCT02082548. FINDINGS:2281 patients from five countries (Argentina, n=343; Brazil, n=360; China, n=586; India, n=493; and Romania, n=499) were enrolled from 48 clusters between June 11, 2014, and Nov 13, 2016. Follow-up was at a median of 12·0 months (IQR 11·8-12·2). Oral anticoagulant use increased in the intervention group from 68% (804 of 1184 patients) at baseline to 80% (943 of 1184 patients) at 1 year (difference 12%), whereas in the control group it increased from 64% (703 of 1092 patients) at baseline to 67% (732 of 1092 patients) at 1 year (difference 3%). Absolute difference in the change between groups was 9·1% (95% CI 3·8-14·4); odds ratio of change in the use of oral anticoagulation between groups was 3·28 (95% CI 1·67-6·44; adjusted p value=0·0002). Kaplan-Meier estimates showed a reduction in the secondary outcome of stroke in the intervention versus control groups (HR 0·48, 95% CI 0·23-0·99; log-rank p value=0·0434). INTERPRETATION: A multifaceted and multilevel educational intervention, aimed to improve use of oral anticoagulation in patients with atrial fibrillation and at risk for stroke, resulted in a significant increase in the proportion of patients treated with oral anticoagulants. Such an intervention has the potential to improve stroke prevention around the world for patients with atrial fibrillation. FUNDING: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer.
RCT Entities:
BACKGROUND: Oral anticoagulation is underused in patients with atrial fibrillation. We assessed the impact of a multifaceted educational intervention, versus usual care, on oral anticoagulant use in patients with atrial fibrillation. METHODS: This study was a two-arm, prospective, international, cluster-randomised, controlled trial. Patients were included who had atrial fibrillation and an indication for oral anticoagulation. Clusters were randomised (1:1) to receive a quality improvement educational intervention (intervention group) or usual care (control group). Randomisation was carried out centrally, using the eClinicalOS electronic data capture system. The intervention involved education of providers and patients, with regular monitoring and feedback. The primary outcome was the change in the proportion of patients treated with oral anticoagulants from baseline assessment to evaluation at 1 year. The trial is registered at ClinicalTrials.gov, number NCT02082548. FINDINGS: 2281 patients from five countries (Argentina, n=343; Brazil, n=360; China, n=586; India, n=493; and Romania, n=499) were enrolled from 48 clusters between June 11, 2014, and Nov 13, 2016. Follow-up was at a median of 12·0 months (IQR 11·8-12·2). Oral anticoagulant use increased in the intervention group from 68% (804 of 1184 patients) at baseline to 80% (943 of 1184 patients) at 1 year (difference 12%), whereas in the control group it increased from 64% (703 of 1092 patients) at baseline to 67% (732 of 1092 patients) at 1 year (difference 3%). Absolute difference in the change between groups was 9·1% (95% CI 3·8-14·4); odds ratio of change in the use of oral anticoagulation between groups was 3·28 (95% CI 1·67-6·44; adjusted p value=0·0002). Kaplan-Meier estimates showed a reduction in the secondary outcome of stroke in the intervention versus control groups (HR 0·48, 95% CI 0·23-0·99; log-rank p value=0·0434). INTERPRETATION: A multifaceted and multilevel educational intervention, aimed to improve use of oral anticoagulation in patients with atrial fibrillation and at risk for stroke, resulted in a significant increase in the proportion of patients treated with oral anticoagulants. Such an intervention has the potential to improve stroke prevention around the world for patients with atrial fibrillation. FUNDING: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer.
Authors: Clare L Atzema; Cynthia A Jackevicius; Alice Chong; Paul Dorian; Noah M Ivers; Ratika Parkash; Peter C Austin Journal: CMAJ Date: 2019-12-09 Impact factor: 8.262
Authors: Gláucia Maria Moraes de Oliveira; Luisa Campos Caldeira Brant; Carisi Anne Polanczyk; Deborah Carvalho Malta; Andreia Biolo; Bruno Ramos Nascimento; Maria de Fatima Marinho de Souza; Andrea Rocha De Lorenzo; Antonio Aurélio de Paiva Fagundes Júnior; Beatriz D Schaan; Fábio Morato de Castilho; Fernando Henpin Yue Cesena; Gabriel Porto Soares; Gesner Francisco Xavier Junior; Jose Augusto Soares Barreto Filho; Luiz Guilherme Passaglia; Marcelo Martins Pinto Filho; M Julia Machline-Carrion; Marcio Sommer Bittencourt; Octavio M Pontes Neto; Paolo Blanco Villela; Renato Azeredo Teixeira; Roney Orismar Sampaio; Thomaz A Gaziano; Pablo Perel; Gregory A Roth; Antonio Luiz Pinho Ribeiro Journal: Arq Bras Cardiol Date: 2022-01 Impact factor: 2.000
Authors: Matthew W Sherwood; Aakriti Gupta; Sreekanth Vemulapalli; Zhuokai Li; Jonathan Piccini; J Kevin Harrison; David Dai; Amit N Vora; Michael J Mack; David R Holmes; John S Rumsfeld; David J Cohen; Vinod H Thourani; Ajay J Kirtane; Eric D Peterson Journal: Circ Cardiovasc Interv Date: 2021-04-20 Impact factor: 6.546
Authors: Aditya Bhat; Shaun Khanna; Henry H L Chen; Arnav Gupta; Gary C H Gan; A Robert Denniss; C Raina MacIntyre; Timothy C Tan Journal: Circ Cardiovasc Qual Outcomes Date: 2021-03-05
Authors: Jeffrey M Ashburner; Steven J Atlas; Shaan Khurshid; Lu-Chen Weng; Olivia L Hulme; Yuchiao Chang; Daniel E Singer; Patrick T Ellinor; Steven A Lubitz Journal: J Gen Intern Med Date: 2018-08-03 Impact factor: 6.473